{"pmid":32425307,"pmcid":"PMC7232064","title":"Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.","text":["Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.","Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14 - 20 days,. However, about 15 % of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (< 65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system.","Med Hypotheses","Rao Us, Vishal","Thakur, Shalini","Rao, Jyothsna","Arakeri, Gururaj","Brennan, Peter A","Jadhav, Sachin","Suhail Sayeed, Mufti","Rao, Gururaj","32425307"],"abstract":["Majority of patients infected with the COVID 19 virus display a mild to moderate course of disease and spontaneously recover at 14 - 20 days,. However, about 15 % of patients progress to severe stages and 2.5% of these patients succumb to this illness. Most patients with severe disease belong to the elderly age group (< 65 years of age) and have multiple associated co-morbidities. The immune responses induced by the COVID 19 virus, during the incubation and non-severe stages, requires the early initiation of a specific adaptive immune response to eliminate the virus and prevent the progress to severe stages. In patients with a dysfunctional bridge adaptive immunity, the innate immune response becomes exaggerated due to the lack of feedback from the adaptive immune cells. The resultant cytokine storm is responsible for the severe lung injury leading to acute respiratory distress syndrome seen in COVID 19 patients. Mesenchymal stem cells are known to suppress overactive immune responses as well as bring about tissue regeneration and repair. This immuno-modulatory effect of MSCs could hold potential to manage a patient with severe symptoms of COVID 19 infection due to a dysfunctional adaptive immune system."],"journal":"Med Hypotheses","authors":["Rao Us, Vishal","Thakur, Shalini","Rao, Jyothsna","Arakeri, Gururaj","Brennan, Peter A","Jadhav, Sachin","Suhail Sayeed, Mufti","Rao, Gururaj"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425307","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.mehy.2020.109845","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837903499264,"score":9.490897,"similar":[{"pmid":32420049,"pmcid":"PMC7224671","title":"Combating COVID-19 with Mesenchymal Stem Cell therapy.","text":["Combating COVID-19 with Mesenchymal Stem Cell therapy.","The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients.","Biotechnol Rep (Amst)","Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant","32420049"],"abstract":["The COVID-19 disease is caused by a positive stranded RNA virus called SARS-CoV-2. The virus mainly targets the pulmonary epithelial cells as it's initial site of infection by letting its surface spike protein interact and bind to the host ACE2 receptor. The internalization and gradual replication of the virus results in an exaggerated immune response triggering release of many pro-inflammatory cytokines and chemokines. This immune storm is responsible for multiple health hazards in the host ultimately leading to multiple organ failure. Mesenchymal stem cell therapy offers a promising approach towards mitigating the delirious effects of the infection in the COVID-19 patients. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. This review has been organized to put forward the positive aruments and implications in support of mesenchymal stem cell therapy as a necessary approach for treating COVID-19 patients."],"journal":"Biotechnol Rep (Amst)","authors":["Rajarshi, Keshav","Chatterjee, Aroni","Ray, Shashikant"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420049","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.btre.2020.e00467","keywords":["covid-19","cytokines","immunomodulatory","mesenchymal stem cells","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284484407296,"score":255.9197},{"pmid":32356908,"title":"Mathematical Modeling of Interaction between Innate and Adaptive Immune Responses in COVID-19 and Implications for Viral Pathogenesis.","text":["Mathematical Modeling of Interaction between Innate and Adaptive Immune Responses in COVID-19 and Implications for Viral Pathogenesis.","We have applied mathematical modeling to investigate the infections of the ongoing COVID-19 pandemic caused by SARS-CoV-2 virus. We first validated our model using the well-studied influenza viruses and then compared the pathogenesis processes between the two viruses. The interaction between host innate and adaptive immune responses was found to be a potential cause for the higher severity and mortality in COVID-19 patients. Specifically the timing mismatch between the two immune responses has a major impact on the disease progression. The adaptive immune response of the COVID-19 patients are more likely to come before the peak of viral load, while the opposite is true for influenza patients. This difference in timing causes delayed depletion of vulnerable epithelial cells in the lungs in COVID-19 patients while enhancing the viral clearance in influenza patients. Stronger adaptive immunity in COVID-19 patients can potentially lead to longer recovery time and more severe secondary complications. Based on our analysis, delaying the onset of adaptive immune responses during early phase of infections may be a potential treatment option for high risk COVID-19 patients. Suppressing the adaptive immune response temporarily and avoiding its interference with the innate immune response may allow the innate immunity to more efficiently clear the virus. This article is protected by copyright. All rights reserved.","J Med Virol","Du, Sean Quan","Yuan, Weiming","32356908"],"abstract":["We have applied mathematical modeling to investigate the infections of the ongoing COVID-19 pandemic caused by SARS-CoV-2 virus. We first validated our model using the well-studied influenza viruses and then compared the pathogenesis processes between the two viruses. The interaction between host innate and adaptive immune responses was found to be a potential cause for the higher severity and mortality in COVID-19 patients. Specifically the timing mismatch between the two immune responses has a major impact on the disease progression. The adaptive immune response of the COVID-19 patients are more likely to come before the peak of viral load, while the opposite is true for influenza patients. This difference in timing causes delayed depletion of vulnerable epithelial cells in the lungs in COVID-19 patients while enhancing the viral clearance in influenza patients. Stronger adaptive immunity in COVID-19 patients can potentially lead to longer recovery time and more severe secondary complications. Based on our analysis, delaying the onset of adaptive immune responses during early phase of infections may be a potential treatment option for high risk COVID-19 patients. Suppressing the adaptive immune response temporarily and avoiding its interference with the innate immune response may allow the innate immunity to more efficiently clear the virus. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Du, Sean Quan","Yuan, Weiming"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356908","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25866","keywords":["adaptive immunity","antiviral drugs","covid-19","immunosuppressive drugs","innate immunity","sars-cov-2","target cell-limited model"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495231459329,"score":232.12555},{"pmid":32505066,"title":"COVID-19: Loss of bridging between innate and adaptive immunity?","text":["COVID-19: Loss of bridging between innate and adaptive immunity?","COVID-19 has spread to most countries in the world. However, there are some striking differences in how COVID-19 is behaving in different age groups. While data on COVID-19 is limited, children appear to be less susceptible to severe disease. These unique characteristics may be considered as a potential link to understanding the immune system and response in COVID-19 and lead to an effective cure to the disease. We suggest a possible role of loss of bridging between innate and adaptive immunity in COVID-19 and a potential treatment modality also discussed.","Med Hypotheses","Rao, Vishal U S","Arakeri, Gururaj","Subash, Anand","Rao, Jyothsna","Jadhav, Sachin","Suhail Sayeed, Mufti","Rao, Gururaj","Brennan, Peter A","32505066"],"abstract":["COVID-19 has spread to most countries in the world. However, there are some striking differences in how COVID-19 is behaving in different age groups. While data on COVID-19 is limited, children appear to be less susceptible to severe disease. These unique characteristics may be considered as a potential link to understanding the immune system and response in COVID-19 and lead to an effective cure to the disease. We suggest a possible role of loss of bridging between innate and adaptive immunity in COVID-19 and a potential treatment modality also discussed."],"journal":"Med Hypotheses","authors":["Rao, Vishal U S","Arakeri, Gururaj","Subash, Anand","Rao, Jyothsna","Jadhav, Sachin","Suhail Sayeed, Mufti","Rao, Gururaj","Brennan, Peter A"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32505066","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109861","keywords":["adaptive immunity","covid-19","cytokines","innate immunity","interferons (ifns)","sars-cov2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488263270402,"score":227.56488},{"pmid":32359201,"title":"The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures.","text":["The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures.","The natural history of COVID-19 caused by SARS-CoV-2 is extremely variable, ranging from asymptomatic or mild infection, mainly in children, to multi-organ failure, eventually fatal, mainly in the eldest. We propose here the first model, explaining how the outcome of first, crucial 10-15 days after infection, hangs on the balance between the cumulative dose of viral exposure and the efficacy of the local innate immune response (natural IgA and IgM antibodies, Mannose Binding Lectin ). If SARS-CoV-2 runs the blockade of this innate immunity and spreads from the upper airways to the alveoli in the early phases of the infections, it can replicate with no local resistance, causing pneumonia and releasing high amounts of antigens. The delayed and strong adaptive immune response (high affinity IgM and IgG antibodies) that follows, causes severe inflammation and triggers mediator cascades (complement, coagulation, and cytokine storm) leading to complications often requiring intensive therapy and being, in some patients, fatal. Low-moderate physical activity can still be recommended. However, extreme physical activity and hyperventilation during the incubation days and early stages of COVID-19, facilitates early direct penetration of high numbers of virus particles in the lower airways and the alveoli, without impacting on the airway's mucosae covered by neutralizing antibodies. This allows the virus bypassing the efficient immune barrier of the upper airways mucosa in already infected, young and otherwise healthy athletes. In conclusion, whether the virus or the adaptative immune response reach the lungs first, is a crucial factor deciding the fate of the patient. This \"quantitative and time-sequence dependent\" model has several implications for prevention, diagnosis, and therapy of COVID-19 at all ages.","Pediatr Allergy Immunol","Matricardi, Paolo Maria","Dal Negro, Roberto Walter","Nisini, Roberto","32359201"],"abstract":["The natural history of COVID-19 caused by SARS-CoV-2 is extremely variable, ranging from asymptomatic or mild infection, mainly in children, to multi-organ failure, eventually fatal, mainly in the eldest. We propose here the first model, explaining how the outcome of first, crucial 10-15 days after infection, hangs on the balance between the cumulative dose of viral exposure and the efficacy of the local innate immune response (natural IgA and IgM antibodies, Mannose Binding Lectin ). If SARS-CoV-2 runs the blockade of this innate immunity and spreads from the upper airways to the alveoli in the early phases of the infections, it can replicate with no local resistance, causing pneumonia and releasing high amounts of antigens. The delayed and strong adaptive immune response (high affinity IgM and IgG antibodies) that follows, causes severe inflammation and triggers mediator cascades (complement, coagulation, and cytokine storm) leading to complications often requiring intensive therapy and being, in some patients, fatal. Low-moderate physical activity can still be recommended. However, extreme physical activity and hyperventilation during the incubation days and early stages of COVID-19, facilitates early direct penetration of high numbers of virus particles in the lower airways and the alveoli, without impacting on the airway's mucosae covered by neutralizing antibodies. This allows the virus bypassing the efficient immune barrier of the upper airways mucosa in already infected, young and otherwise healthy athletes. In conclusion, whether the virus or the adaptative immune response reach the lungs first, is a crucial factor deciding the fate of the patient. This \"quantitative and time-sequence dependent\" model has several implications for prevention, diagnosis, and therapy of COVID-19 at all ages."],"journal":"Pediatr Allergy Immunol","authors":["Matricardi, Paolo Maria","Dal Negro, Roberto Walter","Nisini, Roberto"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359201","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/pai.13271","keywords":["antibodies","covid-19","sars-cov-2","glycans","immunoglobulin m","pneumonia","prediction","protection"],"e_drugs":["Mannose"],"topics":["Diagnosis","Prevention","Treatment","Mechanism"],"weight":1,"_version_":1666138495337365506,"score":207.46925},{"pmid":32425712,"title":"Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.","text":["Evidence Supporting a Phased Immuno-physiological Approach to COVID-19 From Prevention Through Recovery.","This paper presents an evidence-based strategy for improving clinical outcomes in COVID-19. Recommendations are based on the phases of the disease, because optimal interventions for one phase may not be appropriate for a different phase. The four phases addressed are: Prevention, Infection, Inflammation and Recovery. Underlying this phased approach is recognition of emerging evidence for two different components of pathophysiology, early infection and late stage severe complications. These two aspects of the disease suggest two different patterns of clinical emphasis that seem on the surface to be not entirely concordant. We describe the application of therapeutic strategies and appropriate tactics that address four main stages of disease progression for COVID-19. Emerging evidence in COVID-19 suggests that the SARS-CoV-2 virus may both evade the innate immune response and kill macrophages. Delayed innate immune response and a depleted population of macrophages can theoretically result in a blunted antigen presentation, delaying and diminishing activation of the adaptive immune response. Thus, one clinical strategy involves supporting patient innate and adaptive immune responses early in the time course of illness, with the goal of improving the timeliness, readiness, and robustness of both the innate and adaptive immune responses. At the other end of the disease pathology spectrum, risk of fatality in COVID-19 is driven by excessive and persistent upregulation of inflammatory mechanisms associated with cytokine storm. Thus, the second clinical strategy is to prevent or mitigate excessive inflammatory response to prevent the cytokine storm associated with high mortality risk. Clinical support for immune system pathogen clearance mechanisms involves obligate activation of immune response components that are inherently inflammatory. This puts the goals of the first clinical strategy (immune activation) potentially at odds with the goals of the second strategy(mitigation of proinflammatory effects). This creates a need for discernment about the time course of the illness and with that, understanding of which components of an overall strategy to apply at each phase of the time course of the illness. We review evidence from early observational studies and the existing literature on both outcomes and mechanisms of disease, to inform a phased approach to support the patient at risk for infection, with infection, with escalating inflammation during infection, and at risk of negative sequelae as they move into recovery.","Integr Med (Encinitas)","Yanuck, S F","Pizzorno, J","Messier, H","Fitzgerald, K N","32425712"],"abstract":["This paper presents an evidence-based strategy for improving clinical outcomes in COVID-19. Recommendations are based on the phases of the disease, because optimal interventions for one phase may not be appropriate for a different phase. The four phases addressed are: Prevention, Infection, Inflammation and Recovery. Underlying this phased approach is recognition of emerging evidence for two different components of pathophysiology, early infection and late stage severe complications. These two aspects of the disease suggest two different patterns of clinical emphasis that seem on the surface to be not entirely concordant. We describe the application of therapeutic strategies and appropriate tactics that address four main stages of disease progression for COVID-19. Emerging evidence in COVID-19 suggests that the SARS-CoV-2 virus may both evade the innate immune response and kill macrophages. Delayed innate immune response and a depleted population of macrophages can theoretically result in a blunted antigen presentation, delaying and diminishing activation of the adaptive immune response. Thus, one clinical strategy involves supporting patient innate and adaptive immune responses early in the time course of illness, with the goal of improving the timeliness, readiness, and robustness of both the innate and adaptive immune responses. At the other end of the disease pathology spectrum, risk of fatality in COVID-19 is driven by excessive and persistent upregulation of inflammatory mechanisms associated with cytokine storm. Thus, the second clinical strategy is to prevent or mitigate excessive inflammatory response to prevent the cytokine storm associated with high mortality risk. Clinical support for immune system pathogen clearance mechanisms involves obligate activation of immune response components that are inherently inflammatory. This puts the goals of the first clinical strategy (immune activation) potentially at odds with the goals of the second strategy(mitigation of proinflammatory effects). This creates a need for discernment about the time course of the illness and with that, understanding of which components of an overall strategy to apply at each phase of the time course of the illness. We review evidence from early observational studies and the existing literature on both outcomes and mechanisms of disease, to inform a phased approach to support the patient at risk for infection, with infection, with escalating inflammation during infection, and at risk of negative sequelae as they move into recovery."],"journal":"Integr Med (Encinitas)","authors":["Yanuck, S F","Pizzorno, J","Messier, H","Fitzgerald, K N"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425712","source":"PubMed","week":"202021|May 18 - May 24","locations":["optimal"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667252837942296576,"score":202.464}]}